Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Joris Hemelaar, University Research Lecturer and expert in maternal HIV infection at the Nuffield Department of Women's & Reproductive Health, published a new article: "Global and regional epidemiology of HIV-1 recombinants in 1990-2015" in the Lancet HIV.

Front cover of November 2020 Lancet HIV Journal

Global HIV-1 genetic diversity and evolution form a major challenge to treatment and prevention efforts. An increasing number of distinct HIV-1 recombinants have been identified worldwide (106 distinct recombinants to date), but their contribution to the global epidemic was hitherto unknown.

Dr Hemelaar's article: "Global and regional epidemiology of HIV-1 recombinants in 1990-2015: a systematic review and global survey" is the first study to describe the global and regional distribution of HIV-1 recombinants (viruses that are the result of a cross-over between two or more different strains of HIV). This study is based on nearly 400,000 HIV samples covering the period 1990 to 2015. The global and regional distribution of HIV-1 recombinants was found to be extremely diverse and evolve over time. The number and proportion of recombinants is increasing worldwide, reaching 22.8% of global HIV-1 infections in 2010-2015. Recombinants play prominent roles in several regions, including in sub-Saharan Africa, East and South-east Asia, Middle East and North Africa, Eastern Europe and central Asia, and Latin America. This demonstrates the way the HIV pandemic is evolving and highlights the increasing challenge facing the development of a globally effective HIV vaccine as well as the need for ongoing adaptation of HIV diagnostic, drug resistance, and viral load assays.

The full story is available on the Nuffield Department of Women's and Reproductive Health website

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.